g4 software 505 Search Results


90
Dexcom Inc g4 platinum with software 505
G4 Platinum With Software 505, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/g4 platinum with software 505/product/Dexcom Inc
Average 90 stars, based on 1 article reviews
g4 platinum with software 505 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Dexcom Inc rtcgm g4 with software 505
Rtcgm G4 With Software 505, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rtcgm g4 with software 505/product/Dexcom Inc
Average 90 stars, based on 1 article reviews
rtcgm g4 with software 505 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Dexcom Inc g4 software 505
Descriptions of the Four Studies.
G4 Software 505, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/g4 software 505/product/Dexcom Inc
Average 90 stars, based on 1 article reviews
g4 software 505 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Descriptions of the Four Studies.

Journal: Journal of Diabetes Science and Technology

Article Title: The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c

doi: 10.1177/1932296818822496

Figure Lengend Snippet: Descriptions of the Four Studies.

Article Snippet: For analyses reporting baseline data or assessing change from baseline, a minimum of 240 hours (10 days) of masked baseline CGM data were required. provides details of the 4 studies. table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 JDRF CGM RCT a DIAMOND (T1D) REPLACE-BG HypoDE Time period of study February 2007-June 2009 October 2014-May 2016 May 2015-September 2016 March 2016-July 2017 CGM(s) Dexcom Seven, MiniMed Paradigm, Abbott Freestyle Navigator Dexcom G4 with software 505 Dexcom G4 with software 505 Dexcom G5 Method for A1C measurement A1C measured with NGSP-certified method (Tosoh A1c 2.2 Plus Glycohemoglobin Analyzer), performed at University of Minnesota A1C measured with NGSP-certified method (G8 Tosoh Biosciences), performed at Northwest Lipid Research Laboratories, University of Washington, Seattle A1C measured with NGSP-certified method (G8 Tosoh Biosciences), performed at Northwest Lipid Research Laboratories, University of Washington, Seattle A1C measured with NGSP-certified method (G8 Tosoh Biosciences), performed at MLM Medical Labs, Moenchengladbach, Germany A1C eligibility range ≤10.0% 7.5%-9.9% ≤9.0% ≤9.0% Insulin delivery Pump and MDI users (predominately pump) 100% MDI 100% pump users 100% MDI Number of participants included in the analyses 93 99 212 141 Age (years) Mean ± SD 38 ± 13 46 ± 14 45 ± 14 46 ± 11 [Range] [18 to 73] [26 to 72] [20 to 78] [20 to 69] Female % 52 (56%) 43 (43%) 107 (50%) 56 (40%) White race % 90 (97%) 86 (88%) 195 (92%) n/a Diabetes duration (years) Median (IQR) 20 (14-31) 19 (9-31) 23 (15-32) 21 (9-31) [Range] [2 to 63] [2 to 57] [2 to 64] [2 to 54] A1C (%)—baseline Mean ± SD 7.2 ± 0.8 8.6 ± 0.7 7.1 ± 0.6 7.5 ± 1.0 [Range] [4.7 to 9.2] [7.5 to 9.9] [5.2 to 8.7] [4.9 to 10.0] A1C (%)—6 months Mean ± SD 6.8 ± 0.6 7.6 ± 0.8 7.0 ± 0.7 7.3 ± 0.9 [Range] [5.0 to 8.9] [6.0 to 10.1] [5.2 to 8.8] [5.3 to 9.7] A1C—change from baseline (%) Mean ± SD −0.4 ± 0.5 −1.0 ± 0.8 0.0 ± 0.5 −0.2 ± 0.5 [Range] [−2.0 to +0.9] [−3.0 to +0.7] [−1.4 to +1.4] [−1.8 to +1.5] Open in a separate window a Includes both the A1C ≥7.0% and A1C <7.0% cohorts.

Techniques: Software